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In through the Skin
FLG mutations are positively 
associated with atopic 
dermatitis (AD) and 
transepidermal water loss. 
These mutations offer the 
opportunity for environmental 
allergens and food proteins 
to contact the immune 
system. Flohr and colleagues 
demonstrated that early-onset 
AD and disease severity as 
well as skin barrier defects 
were associated with food 
sensitization in a study of 619 
breastfed 3-month-old infants. 
FLG mutation, however, was 
not an independent risk factor 
for food sensitization. The 
relationship between food 
sensitization and atopic disease 
suggests a possible role of 
cutaneous antigen-presenting 
cells in allergies. See page 345
Variability of Variants
Liang and colleagues 
examined single-nucleotide 
polymorphisms in 38 melanoma 
candidate genes in 504 
individuals from melanoma-
prone families with and without 
accompanying mutations in 
CDKN2A, which may confer 
risk for the development 
of dysplastic nevi (DN). DN 
is a strong risk factor for 
melanoma. In this study, CDK6 
and XRCC1 variants were 
significantly associated with 
DN susceptibility. Interestingly, 
neither of these genes was 
associated with cutaneous 
metastatic melanoma, and 
the association with CDK6 
was restricted to patients with 
CDKN2A mutations, suggesting 
that variants may contribute to 
DN risk independently of their 
relationship with melanoma. 
See page 481
Recombinant Correction
Mutations in the filaggrin (FLG) gene underlie 
the epidermal barrier defects of ichthyosis vul-
garis and are features of the murine “flaky tail” 
model. Stout and colleagues demonstrated that 
topical introduction of recombinant FLG mono-
mer protein covalently linked to the human 
immunodeficiency virus transactivator of tran-
scription-derived cell-penetrating peptide (RMR) 
protein motif resulted in internalization and pro-
cessing in epidermal cells. This treatment was 
sufficient to restore the normal phenotype in the 
flaky tail mouse model. Additionally, tissue penetration and cellular uptake of FLG were 
dependent on RMR. These findings support exploration of this strategy in the treatment 
of atopic dermatitis and other genetic barrier defect disorders. See page 423
Cell Reprogramming
In light of recent efforts to alter cellular 
fate through the introduction of specific 
factors, Chen and colleagues reported 
that the introduction of two transcrip-
tion factors (KLF4 and p63) was sufficient 
to convert human fibroblasts to kerati-
nocyte (KC)-like cells, which exhibited 
global gene expression, morphology, and 
chromatin status similar to those of KCs. 
Additionally, these factors induced a KC 
phenotype in a cancer cell line. These 
studies serve as an important starting point 
to determine which factors will further dif-
ferentiate these induced KCs to functional KCs capable of epidermal tissue formation for 
use in regenerative therapies for the many epidermal diseases. See page 335
On the TRAIL
Metastatic melanoma carries a high mortal-
ity due to resistance to chemotherapy and 
the antitumor immune response, stemming 
from defects in proapoptotic signaling. Berger 
and colleagues demonstrated that the pan-
RAF inhibitor L-779,450 inhibited cell pro-
liferation in melanoma. Furthermore, this 
inhibitor enhanced apoptosis with the death 
ligand tumor necrosis factor–related apop-
tosis-inducing ligand (TRAIL) and overcame 
resistance to TRAIL-induced apoptosis in melanoma cells. These findings suggest 
that enhancement of TRAIL sensitivity may support an antitumor immune response. 
Thus, TRAIL receptor agonists together with RAF inhibitors should be examined 
more extensively for their potential for melanoma therapy. See page 430
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